MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
- Jeffrey A. Engelman
- , Kreshnik Zejnullahu
- , Tetsuya Mitsudomi
- , Youngchul Song
- , Courtney Hyland
- , Oh Park Joon
- , Neal Lindeman
- , Christopher Michael Gale
- , Xiaojun Zhao
- , James Christensen
- , Takayuki Kosaka
- , Alison J. Holmes
- , Andrew M. Rogers
- , Federico Cappuzzo
- , Tony Mok
- , Charles Lee
- , Bruce E. Johnson
- , Lewis C. Cantley
- , Pasi A. Jänne
- Massachusetts General Hospital Cancer Center
- Harvard University
- Beth Israel Deaconess Medical Center
- Dana-Farber Cancer Institute
- Aichi Cancer Center Hospital and Research Institute
- Brigham and Women’s Hospital
- Pfizer
- IRCCS Istituto Clinico Humanitas - Rozzano (Milano)
- Chinese University of Hong Kong
Research output: Contribution to journal › Article › peer-review
4294
Link opens in a new tab
Scopus
citations